Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania
- 7 December 2013
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 86 (3) , 404-410
Abstract
The aim of this cross‐sectional study was to evaluate the drug resistance mutationprofile observed in patients receiving antiretroviral therapy with virological failure and to document the HIV‐1 genetic diversity in Mauritania. Eighty‐six subjects were included and 65 samples were amplified successfully and sequenced. HIV‐1 genotyping was performed using the Agence Nationale de Recherche sur le SIDA AC11 resistance procedure. The median treatment duration was 32 months (range: 6–88) and the median viral load, 5 log10 copies/ml (range: 3.13–7). Fifty‐nine patients (90.8%) were on first line regimens including 32.0% (19/59) on triomune fixed‐dose and six on second‐line therapy with NonNucleoside Reverse Transcriptase plus a protease inhibitor. Forty‐seven patients (72.3%) had at least one drug resistance mutation including 73.0% (43/59) on first‐line therapy. For the second‐line, one out of six patients presented resistance mutations and only one presented PI DRM. Overall, the most common DRMs detected were M184V/I (n = 32; 49.2%), K103N (n = 28; 43%), and Y181C (n = 13; 20%). Thymidine Analog Mutations (TAMs) were found in 26.0% (n = 17) of strains and the most common was T215Y (n = 11, 16.9%). Phylogenetic analysis revealed 17 HIV‐1 variants with the predominance of CRF02_AG (n = 42; 64.6%). A high rate of DRM was found in this study and shows the potential need for a structured virological surveillance including viral load quantification and genotyping. Further studies may also be needed in regards to the great variability of HIV‐1 strains in Mauritania. J. Med. Virol. 86:404–410, 2014.Keywords
Funding Information
- Committee Against HIV/AIDS (Mauritania)
- World Bank Multi-Aids Project (MAP)
- Laboratory of Bacteriology-Virology, University Hospital Center Aristide Le Dantec, Dakar, Senegal cofinanced the study
This publication has 25 references indexed in Scilit:
- Characterization of HIV-1 gag and nef in Cameroon: further evidence of extreme diversity at the origin of the HIV-1 group M epidemicVirology Journal, 2013
- Genetic Diversity and Drug Resistance Mutations in HIV-1 from Untreated Patients in Niamey, NigerISRN Microbiology, 2011
- High prevalence of HIV‐1 drug resistance among patients on first‐line antiretroviral treatment in Lomé, TogoJournal of the International AIDS Society, 2011
- Impact of HIV Type 1 Subtype on Drug Resistance Mutations in Nigerian Patients Failing First-Line TherapyAIDS Research and Human Retroviruses, 2011
- Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South AfricaAIDS, 2010
- Molecular diversity and polymerase gene genotypes of HIV-1 among treatment-naïve Cameroonian subjects with advanced diseaseJournal of Clinical Virology, 2010
- Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settingsJournal of Antimicrobial Chemotherapy, 2010
- Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural TanzaniaBMC Infectious Diseases, 2009
- Low Levels of Antiretroviral‐Resistant HIV Infection in a Routine Clinic in Cameroon that Uses the World Health Organization (WHO) Public Health Approach to Monitor Antiretroviral Treatment and Adequacy with the WHO Recommendation for Second‐Line TreatmentClinical Infectious Diseases, 2009
- Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modificationAIDS, 2008